Lyell Immunopharma, Inc. (LYEL) Total liabilities 2020–2025
Lyell Immunopharma, Inc. (LYEL) total liabilities at each fiscal year-end, per SEC filings.
$91.8MFY2025 · since FY2020: $189.8M → $91.8M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $91.8M | -15.0% |
| FY2024 | $108.0M | +13.6% |
| FY2023 | $95.1M | -8.9% |
| FY2022 | $104.3M | -47.2% |
| FY2021 | $197.6M | +4.1% |
| FY2020 | $189.8M | — |
Years the filer does not tag total liabilities directly are shown as reported total assets − reported shareholders’ equity at the same fiscal year-end.
Source: SEC XBRL filings · For reference only · Not investment advice
More LYEL financial trends
LYEL RevenueLYEL Net incomeLYEL Net marginLYEL Gross profitLYEL Gross marginLYEL Operating incomeLYEL Operating marginLYEL Operating cash flowLYEL Free cash flowLYEL Capital expendituresLYEL Return on equityLYEL Stock buybacksLYEL Dividends paidLYEL Total assetsLYEL Shareholders’ equityLYEL overview →